| __timestamp | Intra-Cellular Therapies, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 675200000 |
| Thursday, January 1, 2015 | 18187286 | 771800000 |
| Friday, January 1, 2016 | 24758063 | 1205500000 |
| Sunday, January 1, 2017 | 23666957 | 1146500000 |
| Monday, January 1, 2018 | 30099855 | 1125800000 |
| Tuesday, January 1, 2019 | 64947625 | 1166100000 |
| Wednesday, January 1, 2020 | 186363444 | 1175500000 |
| Friday, January 1, 2021 | 272611040 | 1111400000 |
| Saturday, January 1, 2022 | 358782000 | 1210100000 |
| Sunday, January 1, 2023 | 409864000 | 1274600000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Intra-Cellular Therapies, Inc. and Perrigo Company plc, two giants in the industry, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Intra-Cellular Therapies, Inc. witnessed a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Perrigo Company plc maintained a more stable trajectory, with expenses increasing by approximately 89% over the same period.
These trends highlight differing strategic priorities: while Intra-Cellular focuses on rapid growth, Perrigo emphasizes steady, controlled expansion. Investors and industry analysts should consider these patterns when evaluating the future potential and risk profiles of these companies.
AstraZeneca PLC and Perrigo Company plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Genmab A/S and Intra-Cellular Therapies, Inc.
Neurocrine Biosciences, Inc. or Intra-Cellular Therapies, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Blueprint Medicines Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Veracyte, Inc.
Intra-Cellular Therapies, Inc. and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Mesoblast Limited
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and Perrigo Company plc
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Perrigo Company plc
Selling, General, and Administrative Costs: Perrigo Company plc vs HUTCHMED (China) Limited
Selling, General, and Administrative Costs: Perrigo Company plc vs Geron Corporation